Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


INTERVIEW: Chipscreen CEO Bets Big On Chinese Innovation

This article was originally published in PharmAsia News

Executive Summary

When initial funding burned through and co-founders bailed out, Chipscreen CEO Lu Xianping faced the biggest challenge of his career. A firm belief in scientific evidence and an unwavering confidence in China-originated innovation helped him launch chidamide, a true made in China drug for a rare blood cancer, Lu told PharmAsia News in an exclusive interview.

You may also be interested in...

Huya CEO Mireille Gingras On Partnering To Develop Chinese Compounds In The West: An Interview With PharmAsia News

San Diego-based Huya Bioscience partners with Chinese research institutions and companies to identify preclinical and clinical-stage compounds, including traditional Chinese medicines to license for ex-China development. CEO Mireille Gingras recently spoke with PharmAsia News about Huya's partnership efforts in China. Prior to founding Huya, Gingras was founder and chief operating officer of MIR3, a software company developing online treatment programs for neuro-addictive diseases.

China Approves More Drugs For Cancer, Rare Diseases

BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.

As China Glorifies Traditional Medicines, Doubters See A Haunted Past

In a key step to prop up traditional Chinese medicines, Beijing has proposed a law that could potentially punish any vocal doubters. The move signals a familiar pattern as China resorts to using old approaches when facing a flurry of new challenges.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts